Immunotherapy and immunoevasion of colorectal cancer

IF 6.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2023-09-01 DOI:10.1016/j.drudis.2023.103669

Mohammad Al Zein , Mona Boukhdoud , Hadi Shammaa , Hadi Mouslem , Lemir Majed El Ayoubi , Rabah Iratni , Khodr Issa , Maha Khachab , Hazem I. Assi , Amirhossein Sahebkar , Ali H. Eid

引用次数: 1

Abstract

The tremendous success of immunotherapy in clinical trials has led to its establishment as a new pillar of cancer therapy. However, little clinical efficacy has been achieved in microsatellite stable colorectal cancer (MSS-CRC), which constitutes most CRC tumors. Here, we discuss the molecular and genetic heterogeneity of CRC. We review the immune escape mechanisms, and focus on the latest advances in immunotherapy as a treatment modality for CRC. By providing a better understanding of the tumor microenvironment (TME) and the molecular mechanisms underlying immunoevasion, this review offers an insight into developing therapeutic strategies that are effective for patients with various subsets of CRC.

查看原文本刊更多论文

结直肠癌的免疫治疗与免疫逃避

免疫疗法在临床试验中的巨大成功使其成为癌症治疗的新支柱。然而，在微卫星稳定型结直肠癌(MSS-CRC)中，临床疗效甚微，而微卫星稳定型结直肠癌是结直肠癌的主要肿瘤。在这里，我们讨论结直肠癌的分子和遗传异质性。我们回顾了免疫逃逸机制，并重点介绍了免疫治疗作为结直肠癌治疗方式的最新进展。通过更好地了解肿瘤微环境(TME)和免疫逃避的分子机制，本综述为开发对各种CRC亚群患者有效的治疗策略提供了见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.